Cellmid Ltd
ASX:CDY

Watchlist Manager
Cellmid Ltd Logo
Cellmid Ltd
ASX:CDY
Watchlist
Price: 0.054 AUD 8%
Market Cap: AU$11.9m

Net Margin

-58.2%
Current
No historical data
Comparison unavailable

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-58.2%
=
Net Income
AU$-3.4m
/
Revenue
AU$5.8m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-58.2%
=
Net Income
AU$-3.4m
/
Revenue
AU$5.8m

Peer Comparison

Country Company Market Cap Net
Margin
AU
Cellmid Ltd
ASX:CDY
10.9m AUD
Loading...
FR
L'Oreal SA
PAR:OR
202.8B EUR
Loading...
UK
Unilever PLC
LSE:ULVR
118.1B GBP
Loading...
IN
Hindustan Unilever Ltd
NSE:HINDUNILVR
5.6T INR
Loading...
UK
HALEON PLC
LSE:HLN
33.5B GBP
Loading...
US
Estee Lauder Companies Inc
NYSE:EL
41.5B USD
Loading...
DE
Beiersdorf AG
XETRA:BEI
21.4B EUR
Loading...
JP
Kao Corp
TSE:4452
2.8T JPY
Loading...
IN
Godrej Consumer Products Ltd
NSE:GODREJCP
1.2T INR
Loading...
IN
Dabur India Ltd
NSE:DABUR
914.8B INR
Loading...
CA
Relevium Technologies Inc
XTSX:RLV
12.2B CAD
Loading...

Market Distribution

In line with most companies in Australia
Percentile
46th
Based on 4 004 companies
46th percentile
-58.2%
Low
-16 177 900% — -544.7%
Typical Range
-544.7% — 3.1%
High
3.1% — 3 174 540%
Distribution Statistics
Australia
Min -16 177 900%
30th Percentile -544.7%
Median -27.7%
70th Percentile 3.1%
Max 3 174 540%

Cellmid Ltd
Glance View

Market Cap
11.9m AUD
Industry
Consumer products

Cellmid Ltd. operates as a biotechnology company, which engages in the development and marketing of therapies and diagnostic tests for inflammatory and fibrotic diseases, cancer, ischemic diseases of the heart, and hair loss. The company is headquartered in Sydney, New South Wales. The company went IPO on 2005-12-09. The firm is specialized in developing anti-aging solutions. The firm operates through two segments: Diagnostics and Consumer Health. The firm is engaged in the research and development of diagnostic and therapeutic products for the management of diseases, such as cancer and various chronic inflammatory conditions by targeting midkine. The company is also engaged in the development and sale of over the counter (OTC) and cosmetic products for hair loss and anti-aging hair care through its FGF5 inhibitor technology. The company has developed a range of products under the evolis, evolis Professional, Lexilis Hybrid, Jo-JuRED and Lexilis BLACK brands.

CDY Intrinsic Value
Not Available
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-58.2%
=
Net Income
AU$-3.4m
/
Revenue
AU$5.8m
How has Net Margin changed over time?

Over the last 3 years, Cellmid Ltd’s Net Margin has increased from -64.8% to -58.2%. During this period, it reached a low of -100.2% on Dec 31, 2018 and a high of -50.3% on Dec 31, 2019.

Back to Top